• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GPR40 变构激动剂和肠降血糖素刺激的结构基础。

Structural basis for GPR40 allosteric agonism and incretin stimulation.

机构信息

Lilly Biotechnology Center San Diego, 10290 Campus Point Drive, San Diego, CA, 92121, USA.

Lilly Research Laboratories, Lilly Corporate Center, 355 East Merrill Street, Indianapolis, IN, 46285, USA.

出版信息

Nat Commun. 2018 Apr 25;9(1):1645. doi: 10.1038/s41467-017-01240-w.

DOI:10.1038/s41467-017-01240-w
PMID:29695780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5917010/
Abstract

Activation of free fatty acid receptor 1 (GPR40) by synthetic partial and full agonists occur via distinct allosteric sites. A crystal structure of GPR40-TAK-875 complex revealed the allosteric site for the partial agonist. Here we report the 2.76-Å crystal structure of human GPR40 in complex with a synthetic full agonist, compound 1, bound to the second allosteric site. Unlike TAK-875, which acts as a Gα-coupled partial agonist, compound 1 is a dual Gα and Gα-coupled full agonist. compound 1 binds in the lipid-rich region of the receptor near intracellular loop 2 (ICL2), in which the stabilization of ICL2 by the ligand is likely the primary mechanism for the enhanced G protein activities. The endogenous free fatty acid (FFA), γ-linolenic acid, can be computationally modeled in this site. Both γ-linolenic acid and compound 1 exhibit positive cooperativity with TAK-875, suggesting that this site could also serve as a FFA binding site.

摘要

游离脂肪酸受体 1(GPR40)的合成部分和完全激动剂的激活是通过不同的变构位点发生的。GPR40-TAK-875 复合物的晶体结构揭示了部分激动剂的变构位点。在这里,我们报告了人 GPR40 与合成完全激动剂化合物 1 复合物的 2.76Å 晶体结构,该化合物结合在第二个变构位点上。与作为 Gα 偶联部分激动剂的 TAK-875 不同,化合物 1 是一种双重 Gα 和 Gα 偶联的完全激动剂。化合物 1 结合在受体的富含脂质区域,靠近细胞内环 2(ICL2),配体稳定 ICL2 可能是增强 G 蛋白活性的主要机制。内源性游离脂肪酸(FFA)γ-亚麻酸可以在该部位进行计算建模。γ-亚麻酸和化合物 1 都与 TAK-875 表现出正协同作用,这表明该部位也可以作为 FFA 结合位点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/fbd8552652aa/41467_2017_1240_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/840455e42e16/41467_2017_1240_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/a2d9c92bbc33/41467_2017_1240_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/72987fd75ef7/41467_2017_1240_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/238b91d0d1e6/41467_2017_1240_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/80f6d3e7ee64/41467_2017_1240_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/cdd19a0e8db4/41467_2017_1240_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/679ff446ab33/41467_2017_1240_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/fbd8552652aa/41467_2017_1240_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/840455e42e16/41467_2017_1240_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/a2d9c92bbc33/41467_2017_1240_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/72987fd75ef7/41467_2017_1240_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/238b91d0d1e6/41467_2017_1240_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/80f6d3e7ee64/41467_2017_1240_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/cdd19a0e8db4/41467_2017_1240_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/679ff446ab33/41467_2017_1240_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b292/5917010/fbd8552652aa/41467_2017_1240_Fig8_HTML.jpg

相似文献

1
Structural basis for GPR40 allosteric agonism and incretin stimulation.GPR40 变构激动剂和肠降血糖素刺激的结构基础。
Nat Commun. 2018 Apr 25;9(1):1645. doi: 10.1038/s41467-017-01240-w.
2
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.一种新型抗糖尿病药物法格列净/TAK-875,作为游离脂肪酸受体1(FFAR1)的正向变构调节剂发挥作用。
PLoS One. 2013 Oct 10;8(10):e76280. doi: 10.1371/journal.pone.0076280. eCollection 2013.
3
GPR40-Mediated G12 Activation by Allosteric Full Agonists Highly Efficacious at Potentiating Glucose-Stimulated Insulin Secretion in Human Islets.别构全激动剂通过 GPR40 介导的 G12 激活,在增强人胰岛葡萄糖刺激的胰岛素分泌方面非常有效。
Mol Pharmacol. 2018 Jun;93(6):581-591. doi: 10.1124/mol.117.111369. Epub 2018 Mar 23.
4
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.人源 GPR40 受体与变构激动剂 TAK-875 结合的高分辨率结构。
Nature. 2014 Sep 4;513(7516):124-7. doi: 10.1038/nature13494. Epub 2014 Jul 20.
5
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.GPR40 的激活作为治疗 2 型糖尿病的治疗靶点。
Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S175-9. doi: 10.2337/dcS13-2037.
6
GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.用于治疗2型糖尿病的GPR40激动剂:生物学特性与化学空间
Bioorg Med Chem Lett. 2016 Dec 1;26(23):5603-5612. doi: 10.1016/j.bmcl.2016.10.074. Epub 2016 Oct 26.
7
CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.CPL207280,一种新型的 G 蛋白偶联受体 40/游离脂肪酸受体 1 特异性激动剂,具有良好的安全性特征,并在 2 型糖尿病动物中发挥抗糖尿病作用。
Mol Pharmacol. 2021 Oct;100(4):335-347. doi: 10.1124/molpharm.121.000260. Epub 2021 Aug 4.
8
Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.鉴定游离脂肪酸 1 受体上的多个变构结合位点并对其进行药理学特征分析。
Mol Pharmacol. 2012 Nov;82(5):843-59. doi: 10.1124/mol.112.079640. Epub 2012 Aug 2.
9
Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.基于噻吩-2-基丙酸骨架的强效且口服生物可利用的GPR40完全激动剂的发现。
J Med Chem. 2017 Apr 13;60(7):2697-2717. doi: 10.1021/acs.jmedchem.6b01357. Epub 2017 Mar 17.
10
β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.β-抑制蛋白在游离脂肪酸受体1上的募集及偏向性激动作用
J Biol Chem. 2015 Aug 21;290(34):21131-21140. doi: 10.1074/jbc.M115.644450. Epub 2015 Jul 8.

引用本文的文献

1
A prediction nomogram for mild cognitive impairment in type 2 diabetes mellitus based on the Chinese visceral adiposity index.基于中国内脏脂肪指数的2型糖尿病轻度认知障碍预测列线图。
Sci Rep. 2025 Sep 9;15(1):32393. doi: 10.1038/s41598-025-17241-5.
2
Cryo-EM reveals an extrahelical allosteric binding site at the M mAChR.冷冻电镜揭示了毒蕈碱型乙酰胆碱受体(M mAChR)上的一个螺旋外变构结合位点。
Nat Commun. 2025 Jul 31;16(1):7046. doi: 10.1038/s41467-025-62212-z.
3
Multicolored sequential resonance energy transfer for detection of simultaneous ligand binding at G protein-coupled receptors.

本文引用的文献

1
Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40.游离脂肪酸受体 GPR40 协同变构激活的结构基础。
Nat Struct Mol Biol. 2017 Jul;24(7):570-577. doi: 10.1038/nsmb.3417. Epub 2017 Jun 5.
2
Complex Pharmacology of Free Fatty Acid Receptors.游离脂肪酸受体的复杂药理学。
Chem Rev. 2017 Jan 11;117(1):67-110. doi: 10.1021/acs.chemrev.6b00056. Epub 2016 Jun 14.
3
Extra-helical binding site of a glucagon receptor antagonist.胰高血糖素受体拮抗剂的额外螺旋结合位点。
用于检测G蛋白偶联受体上同时发生的配体结合的多色序列共振能量转移
Nat Commun. 2025 Jul 11;16(1):6413. doi: 10.1038/s41467-025-61690-5.
4
Allosteric modulation and biased signalling at free fatty acid receptor 2.游离脂肪酸受体2的变构调节与偏向性信号传导
Nature. 2025 Jun 18. doi: 10.1038/s41586-025-09186-6.
5
G-Protein-Coupled Receptor (GPCR) Signaling and Pharmacology in Metabolism: Physiology, Mechanisms, and Therapeutic Potential.G蛋白偶联受体(GPCR)在代谢中的信号传导与药理学:生理学、机制及治疗潜力
Biomolecules. 2025 Feb 15;15(2):291. doi: 10.3390/biom15020291.
6
Metabolite-Sensing Receptors: Emerging Targets for Modulating Chronic Pain Pathways.代谢物感应受体:调节慢性疼痛通路的新兴靶点
Curr Issues Mol Biol. 2025 Jan 17;47(1):63. doi: 10.3390/cimb47010063.
7
GPR40-full agonist AM1638 alleviates palmitate-induced oxidative damage in H9c2 cells via an AMPK-dependent pathway.GPR40 完全激动剂 AM1638 通过 AMPK 依赖性途径减轻棕榈酸酯诱导的 H9c2 细胞氧化损伤。
BMB Rep. 2025 Mar;58(3):133-139. doi: 10.5483/BMBRep.2024-0043.
8
Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion.用于微调肠道激素分泌的智能控释脂质基纳米载体。
Sci Adv. 2024 Dec 13;10(50):eadq9909. doi: 10.1126/sciadv.adq9909.
9
A non-canonical mechanism of GPCR activation.G 蛋白偶联受体激活的非经典机制。
Nat Commun. 2024 Nov 16;15(1):9938. doi: 10.1038/s41467-024-54103-6.
10
Combined Physics- and Machine-Learning-Based Method to Identify Druggable Binding Sites Using SILCS-Hotspots.基于物理和机器学习的联合方法,利用 SILCS-Hotspots 识别可成药结合位点。
J Chem Inf Model. 2024 Oct 14;64(19):7743-7757. doi: 10.1021/acs.jcim.4c01189. Epub 2024 Sep 16.
Nature. 2016 May 12;533(7602):274-7. doi: 10.1038/nature17414. Epub 2016 Apr 25.
4
Two disparate ligand-binding sites in the human P2Y1 receptor.人类P2Y1受体中的两个不同配体结合位点。
Nature. 2015 Apr 16;520(7547):317-21. doi: 10.1038/nature14287. Epub 2015 Mar 30.
5
GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo.GPR40(FFAR1)- 在体外结合 Gs 和 Gq 信号传导与体外和体内强大的肠促胰岛素分泌作用相关。
Mol Metab. 2014 Oct 24;4(1):3-14. doi: 10.1016/j.molmet.2014.10.002. eCollection 2015 Jan.
6
Treatment of type 2 diabetes by free Fatty Acid receptor agonists.游离脂肪酸受体激动剂治疗 2 型糖尿病。
Front Endocrinol (Lausanne). 2014 Aug 28;5:137. doi: 10.3389/fendo.2014.00137. eCollection 2014.
7
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.人源 GPR40 受体与变构激动剂 TAK-875 结合的高分辨率结构。
Nature. 2014 Sep 4;513(7516):124-7. doi: 10.1038/nature13494. Epub 2014 Jul 20.
8
Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus.新型 2 型糖尿病口服治疗药物——FFA1 受体激动剂的研究进展。
Bioorg Med Chem Lett. 2014 Jul 15;24(14):2991-3000. doi: 10.1016/j.bmcl.2014.05.019. Epub 2014 May 16.
9
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.一种新型抗糖尿病药物法格列净/TAK-875,作为游离脂肪酸受体1(FFAR1)的正向变构调节剂发挥作用。
PLoS One. 2013 Oct 10;8(10):e76280. doi: 10.1371/journal.pone.0076280. eCollection 2013.
10
Modulating GPR40: therapeutic promise and potential in diabetes.调节GPR40:糖尿病治疗的前景与潜力
Drug Discov Today. 2013 Dec;18(23-24):1301-8. doi: 10.1016/j.drudis.2013.09.003. Epub 2013 Sep 16.